Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Injection symbols : INCY save search
Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $53.85 0.79% 100K
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
drug application injection
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
Published: 2022-01-22 (Crawled : 00:20) - prnewswire.com
INCY | $53.85 0.79% 100K
|
Health Technology
| Email alert
Add to watchlist
LLY | $749.58 -0.16% 450K
|
Health Technology
| Email alert
Add to watchlist
tyvyt cel asco injection results biosimilar biomarkers
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy
Published: 2021-12-24 (Crawled : 11:00) - prnewswire.com
INCY | $53.85 0.79% 100K
|
Health Technology
| Email alert
Add to watchlist
LLY | $749.58 -0.16% 450K
|
Health Technology
| Email alert
Add to watchlist
tyvyt new drug application drug cel lung cancer china therapy injection cancer biosimilar
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021
Published: 2021-11-22 (Crawled : 03:00) - prnewswire.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -1.61%
H: 0.67%
C: -0.68%
INCY | $53.85 0.79% 100K
|
Health Technology
|
| O: -1.1%
H: 0.22%
C: -1.92%
lung cancer therapy injection results cancer phase 3 biosimilar
Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma
Published: 2021-06-28 (Crawled : 01:00) - prnewswire.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.53%
H: 0.38%
C: -0.34%
INCY | $53.85 0.79% 100K
|
Health Technology
|
| O: 1.49%
H: 0.16%
C: -2.85%
china therapy injection approval biosimilar
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
PRSO | $1.79 40.95% 38M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.